glp-1 news oct 9 2025 obesity drug october trends 2025: real-world data, patient outcomes & future therapies Weight Reduction with GLP-1 Agonists – Discounted GLP-1 Weight Loss Drugs

Proceedings of the National Academy of Sciences of the United States of America 106, 1708917094, doi: 10.1073/pnas.0904649106 (2009)

As of April 2025, the FDA received over 1,000 adverse event reports related to compounded semaglutide and tirzepatide

PMID 19913121

Non-surgical interventions include injectable treatments such as dermal fillers, biostimulatory fillers, and autologous fat grafting (lipofilling), as well as energy-based devices like radiofrequency (RF), high-intensity focused ultrasound (HIFU), and fractional lasers

Niacinamide (Vitamin B3):Improves skin texture, reduces pore appearance, and brightens complexion